Literature DB >> 3365692

Possible link between the intrinsic drug resistance of colon tumors and a detoxification mechanism of intestinal cells.

W D Klohs1, R W Steinkampf.   

Abstract

The insensitivity of colon tumors to various anticancer agents was studied in vitro. The activity of Adriamycin (ADR) in several colon tumor cell lines was potentiated by the calcium channel blocker verapamil (VER). In the HCT-8 human colon adenocarcinoma cell line, VER potentiation of the activities of ADR and the anthrapyrazole CI-937 appeared to be related to its ability to enhance the net accumulation of both drugs and inhibit their efflux. VER, which potentiated ADR activity in HCT-8 cells by 4-fold, caused a 3.5-fold stimulation of ADR accumulation and 3.5-fold inhibition of ADR efflux, when compared to non-VER-treated cells. The low level of VER potentiation of CI-937 activity in HCT-8 cells (1.4-fold) was also reflected in CI-937 transport studies which demonstrated a 1.5-fold enhancement of CI-937 accumulation and a 1.4-fold inhibition of its efflux. VER was also found to stimulate ADR activity and accumulation in a normal small intestinal crypt cell line (IEC-6). The mechanism of drug efflux was examined in HCT-8 cells. Agents known to increase the permeability of the plasma membrane did not alter ADR accumulation or its efflux in HCT-8 cells unless these same agents were also capable of interacting with the lysosome. Tween 80 and the lysosomotropic detergent Triton WR-1339 as well as proton ionophores and lysosomotropic amines all stimulated ADR uptake and/or inhibited its efflux from HCT-8 cells. ADR efflux was also partially blocked by cytochalasin B. Based on these observations, we suggest that at least part of the inherent drug resistance of colon tumor cells results from the retention of an enhanced drug efflux mechanism which is found in normal intestinal epithelium where this property may provide protection from plant alkaloids and other xenobiotic agents ingested in the diet. The mechanism of this drug efflux from HCT-8 cells may involve drug partitioning into acidic vesicles within the cell and their subsequent release from these cells by exocytosis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3365692

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Nature's chemicals and synthetic chemicals: comparative toxicology.

Authors:  B N Ames; M Profet; L S Gold
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

2.  Digital cell image analysis of verapamil-induced effects in chemosensitive and chemoresistant neoplastic cell lines.

Authors:  C Etiévant; O Pauwels; R Kiss
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

3.  Expression of the mdr1 gene in human colorectal carcinomas: relationship with multidrug resistance inferred from analysis of human colorectal carcinoma cell lines.

Authors:  G Toffoli; A Viel; L Tumiotto; R Maestro; G Biscontin; M Boiocchi
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 4.  Non-P-glycoprotein multidrug resistance in cell lines which are defective in the cellular accumulation of drug.

Authors:  M S Center
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

5.  Inhibition of P-glycoprotein-mediated vinblastine transport across HCT-8 intestinal carcinoma monolayers by verapamil, cyclosporine A and SDZ PSC 833 in dependence on extracellular pH.

Authors:  J Zacherl; G Hamilton; T Thalhammer; M Riegler; E P Cosentini; A Ellinger; G Bischof; M Schweitzer; B Teleky; T Koperna
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 6.  The multidrug resistance phenotype.

Authors:  S B Kaye
Journal:  Br J Cancer       Date:  1988-12       Impact factor: 7.640

7.  Epithelial secretion of vinblastine by human intestinal adenocarcinoma cell (HCT-8 and T84) layers expressing P-glycoprotein.

Authors:  J Hunter; B H Hirst; N L Simmons
Journal:  Br J Cancer       Date:  1991-09       Impact factor: 7.640

8.  A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance.

Authors:  J Verweij; H Herweijer; R Oosterom; M E van der Burg; A S Planting; C Seynaeve; G Stoter; K Nooter
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

9.  In vitro antitumour activity of cis- and trans-5-fluoro-5,6-dihydro-6-alkoxy-uracils; effects on thymidylate synthesis.

Authors:  C L van der Wilt; G W Visser; B J Braakhuis; R Wedzinga; P Noordhuis; K Smid; G J Peters
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.